Arrivent Biopharma Common Stock Market Value
| AVBP Stock | 22.50 0.07 0.31% |
| Symbol | ArriVent |
Can Stock industry sustain growth momentum? Does ArriVent have expansion opportunities? Factors like these will boost the valuation of ArriVent BioPharma. If investors know ArriVent will grow in the future, the company's valuation will be higher. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating ArriVent BioPharma demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
ArriVent BioPharma Common's market price often diverges from its book value, the accounting figure shown on ArriVent's balance sheet. Smart investors calculate ArriVent BioPharma's intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Since ArriVent BioPharma's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that ArriVent BioPharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether ArriVent BioPharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, ArriVent BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
ArriVent BioPharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to ArriVent BioPharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of ArriVent BioPharma.
| 10/31/2025 |
| 01/29/2026 |
If you would invest 0.00 in ArriVent BioPharma on October 31, 2025 and sell it all today you would earn a total of 0.00 from holding ArriVent BioPharma Common or generate 0.0% return on investment in ArriVent BioPharma over 90 days. ArriVent BioPharma is related to or competes with MeiraGTx Holdings, Replimune, Astria Therapeutics, MBX Biosciences, Ginkgo Bioworks, Iovance Biotherapeutics, and Valneva SE. More
ArriVent BioPharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure ArriVent BioPharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess ArriVent BioPharma Common upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.39 | |||
| Information Ratio | 0.0793 | |||
| Maximum Drawdown | 18.12 | |||
| Value At Risk | (6.03) | |||
| Potential Upside | 6.71 |
ArriVent BioPharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for ArriVent BioPharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as ArriVent BioPharma's standard deviation. In reality, there are many statistical measures that can use ArriVent BioPharma historical prices to predict the future ArriVent BioPharma's volatility.| Risk Adjusted Performance | 0.0769 | |||
| Jensen Alpha | 0.3323 | |||
| Total Risk Alpha | 0.086 | |||
| Sortino Ratio | 0.0938 | |||
| Treynor Ratio | 0.5128 |
ArriVent BioPharma January 29, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0769 | |||
| Market Risk Adjusted Performance | 0.5228 | |||
| Mean Deviation | 3.14 | |||
| Semi Deviation | 3.13 | |||
| Downside Deviation | 3.39 | |||
| Coefficient Of Variation | 1056.97 | |||
| Standard Deviation | 4.01 | |||
| Variance | 16.07 | |||
| Information Ratio | 0.0793 | |||
| Jensen Alpha | 0.3323 | |||
| Total Risk Alpha | 0.086 | |||
| Sortino Ratio | 0.0938 | |||
| Treynor Ratio | 0.5128 | |||
| Maximum Drawdown | 18.12 | |||
| Value At Risk | (6.03) | |||
| Potential Upside | 6.71 | |||
| Downside Variance | 11.48 | |||
| Semi Variance | 9.78 | |||
| Expected Short fall | (3.92) | |||
| Skewness | 0.3525 | |||
| Kurtosis | 0.014 |
ArriVent BioPharma Common Backtested Returns
ArriVent BioPharma appears to be not too volatile, given 3 months investment horizon. ArriVent BioPharma Common secures Sharpe Ratio (or Efficiency) of 0.0946, which signifies that the company had a 0.0946 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for ArriVent BioPharma Common, which you can use to evaluate the volatility of the firm. Please makes use of ArriVent BioPharma's Mean Deviation of 3.14, downside deviation of 3.39, and Risk Adjusted Performance of 0.0769 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, ArriVent BioPharma holds a performance score of 7. The firm shows a Beta (market volatility) of 0.72, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, ArriVent BioPharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding ArriVent BioPharma is expected to be smaller as well. Please check ArriVent BioPharma's expected short fall, and the relationship between the maximum drawdown and rate of daily change , to make a quick decision on whether ArriVent BioPharma's price patterns will revert.
Auto-correlation | 0.29 |
Poor predictability
ArriVent BioPharma Common has poor predictability. Overlapping area represents the amount of predictability between ArriVent BioPharma time series from 31st of October 2025 to 15th of December 2025 and 15th of December 2025 to 29th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of ArriVent BioPharma Common price movement. The serial correlation of 0.29 indicates that nearly 29.0% of current ArriVent BioPharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.29 | |
| Spearman Rank Test | 0.23 | |
| Residual Average | 0.0 | |
| Price Variance | 1.96 |
Pair Trading with ArriVent BioPharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ArriVent BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ArriVent BioPharma will appreciate offsetting losses from the drop in the long position's value.Moving against ArriVent Stock
| 0.49 | NIO | Nio Class A | PairCorr |
| 0.45 | GE | GE Aerospace | PairCorr |
| 0.4 | NVDA | NVIDIA Aggressive Push | PairCorr |
| 0.36 | GRAB | Grab Holdings | PairCorr |
| 0.31 | PLUG | Plug Power | PairCorr |
The ability to find closely correlated positions to ArriVent BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ArriVent BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ArriVent BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ArriVent BioPharma Common to buy it.
The correlation of ArriVent BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ArriVent BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ArriVent BioPharma Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ArriVent BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for ArriVent Stock Analysis
When running ArriVent BioPharma's price analysis, check to measure ArriVent BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ArriVent BioPharma is operating at the current time. Most of ArriVent BioPharma's value examination focuses on studying past and present price action to predict the probability of ArriVent BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ArriVent BioPharma's price. Additionally, you may evaluate how the addition of ArriVent BioPharma to your portfolios can decrease your overall portfolio volatility.